Add a heading 32

Introducing a clinical study for children with Dup15q Syndrome

The Quindecim clinical research study, sponsored by a pharmaceutical company called Roche, is testing the medication Basmisanil in children with Dup15q Syndrome.

Basmisanil is a drug that modulates the activity of a GABAA receptor subtype that is thought to be overactive in dup15q syndrome. In this trial, researchers aim to find out what effects, good or bad, Basmisanil may have compared to a placebo, on motor, language, and social skills of children with Dup15q syndrome and on their ability to do day-to-day activities.

Watch the conference replay below with Dr. Shafali Jeste to learn more about GABAA in dup15q and the dup15q eeg biomarker. 


Quindecim study is currently running and plans to include about 90 children with Dup15q syndrome, between the ages of 2 and 11 years old (inclusive).
Important: If your child does not meet current eligibility requirements, please check back as it is projected two additional groups may open.


Current US Locations Enrolling: *more locations expected to open in 2023

RUSH University Medical Center in Chicago
1620 W. Harrison St., Chicago, IL 60612

Interested in Enrolling at Rush?

Children’s Hospital Los Angeles 
4650 W Sunset Blvd, Los Angeles, CA 90027

Interested in Enrolling at CHLA?

Learn More

To learn more about the study, please talk to your doctor and check the following resources:

Study: Clinical Trial – Dup15q Syndrome – Safety, Efficacy, and Pharmacodynamics of Basmisanil | ForPatients-Roche

Dup15q Alliance is not affiliated with, nor has any financial investment in these Studies. Dup15q Alliance is sharing information about these external partner opportunities, and is not sponsoring nor is directly involved in these partner projects. Should you choose to reach out to any of the Studies and/or become involved, you would do so independently from Dup15q Alliance.